CHI PHÍ HIỆU QUẢ CỦA THUỐC KẾT HỢP SALMETEROL/FLUTICASONE PROPIONATE TRONG ĐIỀU TRỊ HEN PHẾ QUẢN KHÔNG KIỂM SOÁT TẠI VIỆT NAM

Abstract

Objectives: To evaluate the cost-effectiveness of salmeterol/fluticasone propionate (Seretide®) versus inhaled corticosteroids (ICS) in the treatment of uncontrolled asthma in Vietnam. Methods: A model-based cost utility analysis from payer’s perspective was conducted. The model consists of two main health states: disease without symptom and with symptom to simulate the natural history of the disease over a one-year time horizon with a weekly cycle. The parameter of the drug’s efficacy was derived from a published meta-analysis. The cost of drugs is collected from the results of bidding results and the results of price negotiations by the Ministry of Health. The cost of treatment is estimated based on the resources required according to treatment guidelines combined with clinical expert consultation multiplied by the technical service unit price prescribed by the Ministry of Health.  Results: salmeterol/fluticasone propionate dominates the ICS same dose or increased doses ICS in all scenarios of low, moderate, and high dose. The results of the sensitivity analysis confirm the robustness and reliability of the model’s results. Conclusions: For patients with inadequately controlled asthma on ICS, choosing an ICS/LABA regimen such as salmeterol/fluticasone is a cost-effective solution.